Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58 million

We have advised Nuclera, the pioneer in making biology accessible to everyone through desktop bioprinting, on raising an additional $15.5 million in Series B financing which brings the total to $58 million. Nuclera will use the additional investments from Jonathan Milner and Verve Ventures to accelerate the commercial launch of its eProtein™ desktop bioprinter. 

Historically, making proteins has been a time-consuming and complex process, taking weeks, months, or even years for a scientist to obtain the required protein samples. However, Nuclera's eProtein™ bioprinter combines cell-free protein synthesis and digital microfluidics to create a novel technology platform that solves this problem within days, revolutionising the fragmented protein expression process into a single optimised, end-to-end workflow for drug discovery and general bio-innovation.  

The eProtein™ bioprinter will allow researchers to accelerate discoveries and treatments by delivering on-demand, rapid access. Researchers will soon be able to seamlessly move from protein screening to scaled-up expression on an accelerated time frame in all market segments.

In the near-term, Nuclera will further expand personnel across key functions in order to accelerate through the pre-commercial phase and bring their innovative technology to market.

Commenting on the transaction, corporate partner Ross McNaughton said: "We are thrilled to continue building on our close partnership with Michael and the Nuclera team by advising on their latest fundraise. They are truly revolutionising access to biology with their bioprinter and this raise will take them a step closer to bringing their cutting-edge technology to market. We look forward to providing further support as the business continues its exceptional growth."

Co-founder and Nuclera CEO Michael Chen added “We’re delighted by the continued support from our existing investors and to have the opportunity to bring on several new strategic partners with our recent Series B raise. We are grateful to the excellent Taylor Wessing team who have once again provided us with outstanding legal support and guidance. We can always rely on them for their deep sector knowledge and strategic, commercially focused advice which have been vital in achieving this strong result." 

The team was led by partners Ross McNaughton and Adrian Toutoungi with support from associate Oli Denne.